Tenax Therapeutics Q2 FY26 net loss widens to $17.8 million; R&D expenses more than doubled to $12.9 million

• Tenax Therapeutics posted a Q2 net loss that widened to $17.8 million from $10.9 million a year earlier.
• R&D expense more than doubled to $12.9 million, driven by higher Phase 3 costs for LEVEL and LEVEL-2.
• Cash and equivalents rose to $118 million; $13.4 million of warrant exercises extended the cash runway into Q2 2028.
• Topline data from the Phase 3 LEVEL trial are expected in August 2026, with results slated for a late-breaking session at ESC Congress 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310700PRIMZONEFULLFEED9801302) on July 31, 2026, and is solely responsible for the information contained therein.